Phenotype of bronchial asthma with fixed obstruction

Мұқаба

Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

A characteristic feature of bronchial asthma (BA) is reversible airflow obstruction, which is quickly relieved by short-acting bronchodilators. However, incomplete reversibility (spirometry results do not return to normal despite treatment), also called fixed bronchial obstruction (FBO), occurs in 60% of patients with severe asthma. Patients with asthma with FBO represent a special cohort characterized by a severe course of the disease and reluctance to therapy with high doses of inhaled corticosteroids. The phenotype of BS with FBO requires additional study to determine the volume and choice of therapy.

Толық мәтін

Рұқсат жабық

Авторлар туралы

E. Kostina

Penza Institute for Advanced Training of Physicians – Branch Campus of RMACPE

Email: trushina.lena@mail.ru
ORCID iD: 0000-0003-1797-8040
SPIN-код: 2111-8827
Ресей, Penza

Elena Trushina

Penza Institute for Advanced Training of Physicians – Branch Campus of RMACPE

Хат алмасуға жауапты Автор.
Email: trushina.lena@mail.ru
ORCID iD: 0000-0001-5673-9195
SPIN-код: 2164-6580

Cand. Sci. (Med.), Associate Professor at the Department of Pulmonology and Phthisiology

Ресей, Penza

V. Tipikin

Penza Institute for Advanced Training of Physicians – Branch Campus of RMACPE

Email: trushina.lena@mail.ru
ORCID iD: 0009-0000-0990-4661
SPIN-код: 7403-8592
Ресей, Penza

E. Orlova

Penza Institute for Advanced Training of Physicians – Branch Campus of RMACPE

Email: trushina.lena@mail.ru
ORCID iD: 0000-0002-3902-2018
SPIN-код: 1700-4848
Ресей, Penza

Әдебиет тізімі

  1. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. 2023. Accessed June 10, 2023. URL: https://ginasthma.org/wp-content/uploads/2023/05/GINA-2023-Full-Report-2023-WMS.pdf
  2. Tamada T., Sugiura H., Takahashi T., et al. Coexisting COPD in elderly asthma with fixed airflow limitation: Assessment by DLco% predicted and HRCT. J Asthma 2017;54:606-15. doi: 10.1080/02770903.2016.1247168.
  3. Hekking P.W., Wener R.R., Amelink M., et al. The prevalence of severe refractory asthma. J Allergy Clin Immunol. 2015;135:896–902. doi: 10.1016/j.jaci.2014.08.042.
  4. Lee J.H., Haselkorn T., Borish L., et al. Risk factors associated with persistent airflow limitation in severe or difficult-to-treat asthma: Insights from the TENOR study. Chest. 2007;132:1882–89. doi: 10.1378/chest.07-0713.
  5. Poon A.H., Eidelman D.H., Martin J.G., et al. Pathogenesis of severe asthma. Clin Exp Allergy. 2012;42:625–37. doi: 10.1111/j.1365-2222.2012.03983.x.
  6. Kyriakopoulos C., Gogali A., Bartziokas K., Kostikas K. Identification and treatment of T2-low asthma in the era of biologics. ERJ Open Res. 2021;7:00309–2020. doi: 10.1183/23120541.00309-2020.
  7. Zaihra T., Walsh C.J., Ahmed S., et al. Phenotyping of difficult asthma using longitudinal physiological and biomarker measurements reveals significant differences in stability between clusters. BMC Pulm. Med. 2016;16:74. doi: 10.1186/s12890-016-0232-2.
  8. Dweik R.A., Sorkness R.L., Wenzel S., et al. Use of exhaled nitric oxide measurement to identify a reactive, at-risk phenotype among patients with asthma. Am J Respir Crit Care Med. 2010;181:1033–41. doi: 10.1164/rccm.200905-0695OC.
  9. Haldar P., Pavord I.D., Shaw D.E., et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med. 2008;178:218–24. doi: 10.1164/rccm.200711-1754OC.
  10. Wenzel S.E. Asthma phenotypes: The evolution from clinical to molecular approaches. Nat Med. 2012;18:716–25. doi: 10.1038/nm.2678.
  11. Moore W.C., Meyers D.A., Wenzel S.E., et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med. 2010;181:315–23. doi: 10.1164/rccm.200906-0896OC.
  12. McDowell P.J., Heaney L.G. Different endotypes and phenotypes drive the heterogeneity in severe asthma. Allergy. 2020;75:302–10. doi: 10.1111/all.13966.
  13. Israel E., Reddel H.K. Severe and Difficult-to-Treat Asthma in Adults. N Engl J Med. 2017;377:965–76. doi: 10.1056/NEJMra1608969.
  14. Mogensen I., Alving K., Dahlen S.E., et al. Fixed airflow obstruction relates to eosinophil activation in asthmatics. Clin Exp Allergy. 2019;49:155–62. doi: 10.1111/cea.13302.
  15. Woodruff P.G., Modrek B., Choy D.F., et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med. 2009;180:388–95. doi: 10.1164/rccm.200903-0392OC.
  16. Kanemitsu Y., Matsumoto H., Izuhara K., et al. Increased periostin associates with greater airflow limitation in patients receiving inhaled corticosteroids. J Allergy Clin Immunol. 2013;132:305–12.e3. doi: 10.1016/j.jaci.2013.04.050.
  17. van Veen I.H., Ten Brinke A., Sterk P.J., et al. Exhaled nitric oxide predicts lung function decline in difficult-to-treat asthma. Eur Respir J. 2008;32:344–49. doi: 10.1183/09031936.00135907.
  18. Mogensen I., Jacinto T., Alving K., et al. Inflammatory patterns in fixed airflow obstruction are dependent on the presence of asthma. PLoS ONE. 2020;15:e0243109. doi: 10.1371/journal.pone.0243109.
  19. ten Brinke A., Zwinderman A.H., Sterk P.J., et al. Factors associated with persistent airflow limitation in severe asthma. Am J Respir Crit Care Med. 2001;164:744–48. doi: 10.1164/ajrccm.164.5.2011026.
  20. Denlinger L.C., Phillips B.R., Ramratnam S., et al. Inflammatory and Comorbid Features of Patients with Severe Asthma and Frequent Exacerbations. Am J Respir Crit Care Med. 2017;195:302–13. doi: 10.1164/rccm.201602-0419OC.
  21. Simpson J.L., Scott R., Boyle M.J., Gibson P.G. Inflammatory subtypes in asthma: Assessment and identification using induced sputum. Respirology. 2006;11:54–61. doi: 10.1111/j.1440-1843.2006.00784.x.
  22. Костина Е.Ю., Трушина Е.Ю. Роль нейтрофильной эластазыи IL-8 в патогенезе типа воспаления у больных неаллергической бронхиальной астмой. Здоровье и образование в XXI веке. 2019;21(3):22–6. [Kostina Е.М., Trushina E.Yu. Neutrophilic elastase and IL-8 role in the inflammation type pathogenesis in patients withnonallergical bronchial asthma. Health and Education XXI. 2019;21(3):22–6. (In Russ.)].
  23. Gibson P.G., Simpson J.L., Saltos N. Heterogeneity of airway inflammation in persistent asthma: Evidence of neutrophilic inflammation and increased sputum interleukin-8. Chest. 2001;119:1329–36. doi: 10.1378/chest.119.5.1329.
  24. Smith B.M., Zhao N., Olivenstein R., et al. Asthma and fixed airflow obstruction: Long-term trajectories suggest distinct endotypes. Clin Exp Allergy. 2021;51:39–48. doi: 10.1111/cea.13714.
  25. Shaw D.E., Berry M.A., Hargadon B., et al. Association between neutrophilic airway inflammation and airflow limitation in adults with asthma. Chest. 2007;132:1871–75. doi: 10.1378/chest.07-1047.
  26. Zhang L., He L., Gong J., Liu C. Risk Factors Associated with Irreversible Airway Obstruction in Asthma: A Systematic Review and Meta-Analysis. Biomed Res Int. 2016;2016:9868704. doi: 10.1155/2016/9868704.
  27. Guerra S., Sherrill D.L., Kurzius-Spencer M., et al. The course of persistent airflow limitation in subjects with and without asthma. Respir Med. 2008;102:1473–82. doi: 10.1016/j.rmed.2008.04.011.
  28. Rutting S., Chapman D.G., Badal T., et al. Higher body mass index is associated with increased lung stiffness and less airway obstruction in individuals with asthma and fixed airflow obstruction. ERJ Open Res. 2021;7:00336–2020. doi: 10.1183/23120541.00336-2020.
  29. den Dekker H.T., Sonnenschein-van der Voort A.M.M., de Jongste J.C., et al. Early growth characteristics and the risk of reduced lung function and asthma: A meta-analysis of 25,000 children. J Allergy Clin Immunol. 2016;137:1026–35. doi: 10.1016/j.jaci.2015.08.050.
  30. Sousa A.W., Barros Cabral A.L., Arruda Martins M., Carvalho C.R.F. Risk factors for fixed airflow obstruction in children and adolescents with asthma: 4-Year follow-up. Pediatric Pulmonol. 2020;55:591–98. doi: 10.1002/ppul.24625.
  31. Tashkin D.P., Chipps B.E., Trudo F., Zangrilli J.G. Fixed airflow obstruction in asthma: A descriptive study of patient profiles and effect on treatment responses. J Asthma. 2014;51:603–9. doi: 10.3109/02770903.2014.895012.
  32. Lee L., Kerwin E., Collison K., et al. The effect of umeclidinium on lung function and symptoms in patients with fixed airflow obstruction and reversibility to salbutamol: A randomised, 3-phase study. Respir Med. 2017;131:148–57. doi: 10.1016/j.rmed.2017.08.013.
  33. Langton D., Ing A., Fielding D., et al. Bronchodilator responsiveness as a predictor of success for bronchial thermoplasty. Respirology. 2019;24:63–7. doi: 10.1111/resp. 13375.
  34. Chaudhuri R., Livingston E., McMahon A.D., et al. Effects of smoking cessation on lung function and airway inflammation in smokers with asthma. Am J Respir Crit Care Med. 2006;174:127–33. doi: 10.1164/rccm.200510-1589OC.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2024

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>